🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We shared Q1 2025 results today, highlighting progress on our DM1 and DMD programs that have both demonstrated functional improvement through their ongoing clinical trials. Full update: bit.ly/4m1eu0J $DYN

Attending PEGS Summit? Catch our presentation on how our FORCE™ Platform enables delivery of novel therapeutics for neuromuscular disorders. See the agenda: bit.ly/38oC0nf

Real-world findings from our IMPaCT study of DM1 are being shared at ISPOR 2025, reinforcing the urgent need for therapies that address the multi-systemic nature of the disease. Check out the agenda: bit.ly/44uiCA8 #ISPORAnnual

Join us at ASGCT 2025, where we’ll share presentations on our FORCE™ platform, as well as previously announced data from our ACHIEVE trial in DM1 demonstrating meaningful functional improvement: bit.ly/4kcyyLM #ASGCT2025

At #TIDESUSA, we’ll share a presentation on how our FORCE™ platform leverages the transferrin receptor to enable delivery of novel therapeutics and demonstrates translatability into the clinic. Learn more: bit.ly/4dnCesd TIDES - Informa Connect

Join us for our presentation at the CureDuchenne Futures conference during the industry update session to learn about our recent DMD data from DYNE-251 in the exon 51 skip amenable population showing functional improvement: bit.ly/4kx6SBE #2025FUTURES

Headed to the AIM National Congress? Hear leading experts in neuromuscular disease explore how our FORCE™ platform is helping to deliver sustained functional improvement to people living with these genetically driven diseases: bit.ly/4ky8bAn

In our latest FORCEs in Biotech conversation, Dyne board member Dr. Catherine Stehman-Breen shares insights on building transformative biotech companies and keeping patients at the center of innovation.

On June 4, we will host a webinar with Parent Project Muscular Dystrophy (PPMD) as we present recent data from our DELIVER trial of DYNE-251 in individuals with DMD who are amenable to exon 51 skipping. Register: bit.ly/4kkQ5ls

Dyne is presenting new preclinical data on DYNE-302 at this year’s FSHD Society IRC, reinforcing the potential of the FORCE™ platform to achieve functional improvement in FSHD: bit.ly/4dM1oRf

Thank you to all of our #Dynamos who joined the Jett Foundation’s National Challenge with a walk in our local park to raise awareness and funds for the #DMD community! You can make a difference too. Donate today and help us fuel hope and progress: bit.ly/4jwH8oK

FSHD Connect, hosted by FSHD Society and FSHD Europe, brings together individuals living with #FSHD, their families, researchers and advocates. We look forward to engaging with the community and discussing the latest research and progress: bit.ly/3FGBXEj

We were thrilled to recently host Dr. Johanna Hamel at Dyne. She shared how expanding access to research through remote assessments and patient registries helps capture the full story of #MyotonicDystrophy.

Tomorrow, June 17, we will host a webcast to provide an update on DYNE-101 in DM1 Join us at 8:00 a.m. ET: bit.ly/3FRUEoA $DYN

DYNE-101 received Breakthrough Therapy Designation for DM1 from U.S. FDA. New long-term data support its promise to deliver meaningful functional improvement as we advance toward potential U.S. Accelerated Approval. Learn more: bit.ly/4laT9Rn $DYN

We’re excited to join the #Duchenne community for the Parent Project Muscular Dystrophy (PPMD)’s 2025 Annual Conference! Register to visit us either virtually or in person at our booth: bit.ly/444t0wF

Dyne CIO Oxana Beskrovnaya is joining leaders at #BIO2025 to discuss what’s driving the “RNAissance” and how RNA therapeutics are reshaping drug development. Learn more: bit.ly/3HL2GQy

This #WorldFSHDDay, we're proud to support the FSHD Society and raise awareness of FSHD and its impact – including the loss of the ability to smile. Learn more and get involved: bit.ly/3xmOSXP

On Dyne Science Day, our #Dynamos shared the research and innovation driving our goal to deliver meaningful functional improvement for people with neuromuscular diseases. Grateful for a team that never stops pushing science forward.

This July, join the Myotonic Dystrophy Foundation community for Myotonic Dystrophy in Motion Awareness Month to support wellness for people living with DM. Get involved with weekly activities, expert webinars and ways to connect: bit.ly/40lcXJZ